Acorda Therapeutics Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) today and set a price target of $31. The company’s shares closed yesterday at $23.20.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 35.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Acorda Therapeutics is Moderate Buy and the average price target is $26.83, representing a 15.6% upside.

In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.60 and a one-year low of $13.60. Currently, Acorda Therapeutics has an average volume of 499.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company’s two main products are Ampyra and Zanaflex Capsules.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts